DuPont de Nemours (DD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Werte in diesem Artikel
For the quarter ended September 2025, DuPont de Nemours (DD) reported revenue of $3.07 billion, down 3.8% over the same period last year. EPS came in at $1.09, compared to $1.18 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.63 billion, representing a surprise of +16.94%. The company delivered an EPS surprise of +4.81%, with the consensus EPS estimate being $1.04.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how DuPont de Nemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- IndustrialsCo: $1.8 billion versus $2.1 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +30% change.Net Sales- ElectronicsCo: $1.28 billion compared to the $1.22 billion average estimate based on two analysts. The reported number represents a change of -17.8% year over year.Operating EBITDA- ElectronicsCo: $403 million compared to the $394.86 million average estimate based on two analysts.Operating EBITDA- Corporate & Other: $-28 million compared to the $-34 million average estimate based on two analysts.Operating EBITDA- IndustrialsCo: $465 million versus $515.11 million estimated by two analysts on average.View all Key Company Metrics for DuPont de Nemours here>>>Shares of DuPont de Nemours have returned -49.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DuPont de Nemours, Inc. (DD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: DuPont de Nemours und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf DuPont de Nemours
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DuPont de Nemours
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Zacks
Nachrichten zu DuPont de Nemours
Analysen zu DuPont de Nemours
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
| 20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
| 25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
| 10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
| 06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 04.10.2021 | DuPont de Nemours Overweight | JP Morgan Chase & Co. | |
| 20.08.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
| 10.06.2019 | DowDuPont Outperform | Cowen and Company, LLC | |
| 12.10.2018 | DowDuPont buy | Deutsche Bank AG | |
| 29.03.2018 | DowDuPont Outperform | BMO Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 25.06.2019 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
| 06.02.2019 | DowDuPont Market Perform | Cowen and Company, LLC | |
| 12.09.2017 | DowDuPont Neutral | Monness, Crespi, Hardt & Co. | |
| 31.05.2017 | Dow Chemical Market Perform | Cowen and Company, LLC | |
| 26.04.2017 | DuPont (E I DuPont de Nemours and Sector Perform | RBC Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.01.2009 | Dow Chemical verkaufen | Euro am Sonntag | |
| 11.04.2007 | Dow Chemical verkaufen | Hamburger Sparkasse | |
| 03.02.2006 | Update Rohm and Haas Co.: Reduce | UBS | |
| 07.07.2005 | Update Rohm and Haas Co.: Sell | Longbow |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DuPont de Nemours nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen